Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors Roche
- 23 May 2013 Planned end date changed from 1 Jan 2014 to 1 May 2013 as reported by ClinicalTrials.gov record.
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2012 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.